Emergency Medicine Cardiac Research and Education Group


CRUSADE
CRUSADE Quality Improvement Initiative

Launched in 2001, CRUSADE is a national quality improvement initiative, designed to increase the practice of evidence-based medicine for patients diagnosed with non-ST segment elevation acute coronary syndromes (NSTE ACS) (i.e., unstable angina or NSTE myocardial infarction).

Through a continuous cycle of data collection, performance feedback and quality improvement interventions, over 500 participating sites in the US are consistently improving the standard of care for patients with NSTE ACS. Because of the dedication of the participating hospitals to this mission, over 200,000 cases have been submitted to the CRUSADE database. For more information visit the CRUSADE website.

In 2007, a milestone occurred. Duke Clinical Research Institute and its CRUSADE leadership joined forces with the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR™) to launch a new initiative to improve the safety and outcomes for patients with ACS through the development of NCDR-ACTION™. This initiative will combine the data collection and quality reporting features of two leading national ACS registries to create the largest and most comprehensive national cardiovascular patient database ever developed. For more information visit the NCDR-ACTION Registry™ visit the website or call 800-257-4737 for more information.




An Assessment of Incremental Coronary Risk Prediction Using C-Reactive Protein and Other Novel Risk Markers The Atherosclerosis Risk in Communities Study



Arch Intern Med. 2006;166:1368-1373View the citation

Background> There has been interest in recent years in whether additional, and in particular novel, risk factors or blood markers, such as C-reactive protein, can enhance existing coronary heart disease (CHD) prediction models.

Methods Using a series of case-cohort studies, the prospective Atherosclerosis Risk in Communities (ARIC) Study assessed the association of 19 novel risk markers with incident CHD in 15 792 adults followed up since 1987-1989. Novel markers included measures of inflammation, endothelial function, fibrin formation, fibrinolysis, B vitamins, and antibodies to infectious agents. Change in the area under the receiver operating characteristic curve (AUC) was used to assess the additional contribution of novel risk markers to CHD prediction beyond that of traditional risk factors.

ResultsThe basic risk factor model, which included traditional risk factors (age, race, sex, total and high-density lipoprotein cholesterol levels, systolic blood pressure, antihypertensive medication use, smoking status, and diabetes), predicted CHD well, as evidenced by an AUC of approximately 0.8. The C-reactive protein level did not add significantly to the AUC (increase in AUC of 0.003), and neither did most other novel risk factors. Of the 19 markers studied, lipoprotein-associated phospholipase A2, vitamin B6, interleukin 6, and soluble thrombomodulin added the most to the AUC (range, 0.006-0.011).

Conclusions Our findings suggest that routine measurement of these novel markers is not warranted for risk assessment. On the other hand, our findings reinforce the utility of major, modifiable risk factor assessment to identify individuals at risk for CHD for preventive action.




General navigation: Home | Member roster | Consultation | Our history | Contact
News & Events: Literature news archives | EM and related events
Education: Symposium monographs | CME monographs | Articles & Print | Multimedia
Publications: Member publications | Monographs

Legal information

EMCREG™ - International
Department of Emergency Medicine
University of Cincinnati College of Medicine
ML 0769, Room 6107
231 Albert Sabin Way
Cincinnati, Ohio 45267-0769

Fell free to contact us toll-free at 1-866-4EMCREG (436-2734)



Advanced Search

28 January 2010
Study results show that the TIMI risk score predicts outcomes in in emergency department with suspected ACS.
28 January 2010
Serial measurement of NT-proBNP predicts new-onset heart failure and cardiovascular mortality in elderly.
15 January 2010
Individual risk profiling of ACS patients could optimize therapeutic treatment choices.
15 January 2010
Results of the PLATO trial show that the reversible P2Y12 inhibitor ticagrelor reduces death and cardiovascular events compared with clopidogrel therapy in ACS patients.
5 January 2010
Study shows that high sensitive cardiac troponin I level is a useful prognostic marker of mortality in chronic heart failure patients.
23 December 2009
The largest and most comprehensive meta-analysis ever concludes that CRP is unlikely to be a causal factor for cardiovascular disease.
16 December 2009
Research shows that a substantial number of STEMI patients still receive fibrinolytic therapy at PCI capable centers.
11 December 2009
Denmark researchers report in Lancet that relative risk for hospitalization for bleeding increased with all drug combinations and with each additional drug used.
3 December 2009
Researchers report that prehospital triage significantly reduces treatment delay and improves outcomes in STEMI patients who undergo PCI.
30 November 2009
Researchers report that the to reperfusion, beginning with symptom onset time, determines the extent of reversible myocardial injury in STEMI patients undergoing PCI.
19 November 2009
Data presented at the AHA 2009 Scientific Sessions shows that dabigatran when added to dual anti-platelet therapy results in a “low and acceptable bleeding rate” in AMI patients.
19 November 2009
A must-read update for the management of acute coronary syndrome.
19 November 2009
Data presented at the AHA 2009 Scientific Sessions indicates that CT angiography in the emergency room can successfully triage at-risk chest-pain patients faster and cheaper than standard of care testing.
19 November 2009
Recent meta-analysis reveals that high-risk STEMI patients given adjunctive glycoprotein (GP) IIb/IIIa inhibitor therapy and undergo primary angioplasty have a reduced risk for death.
NEWS ARCHIVES:
©Copyright EMCREG-International™. All rights reserved